Reuters - Takeda Pharmaceutical Co's Velcade reduced the risk of death by 31 percent when used in combination with standard medicines in previously untreated multiple myeloma patients, according to five-year follow-up data from a late stage clinical trial.
You are here:
Health 
Diseases & Conditions Takeda drug cuts myeloma death risk in 5-year study
(Reuters)
Diseases & Conditions Takeda drug cuts myeloma death risk in 5-year study
(Reuters)
